Premium
Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan
Author(s) -
Fukano Reiji,
Mori Tetsuya,
Kobayashi Ryoji,
Mitsui Tetsuo,
Fujita Naoto,
Iwasaki Fuminori,
Suzumiya Junji,
Chin Motoaki,
Goto Hiroaki,
Takahashi Yoshiyuki,
Hara Junichi,
Park YongDong,
Inoue Masami,
Koga Yuhki,
Inagaki Jiro,
Sakamaki Hisashi,
Adachi Souichi,
Kawa Keisei,
Kato Koji,
Suzuki Ritsuro
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13167
Subject(s) - medicine , hematopoietic stem cell transplantation , refractory (planetary science) , cumulative incidence , lymphoma , transplantation , gastroenterology , chemotherapy , incidence (geometry) , adverse effect , hematology , oncology , surgery , physics , astrobiology , optics
Summary To evaluate haematopoietic stem cell transplantation ( HSCT ) in children and adolescents, we reviewed the records of 47 patients who were ≤18 years, had relapsed or refractory anaplastic large cell lymphoma, and received HSCT between 1990 and 2010. At HSCT , complete remission ( CR ) was less common in allogeneic HSCT recipients ( n = 24) than in autologous HSCT recipients ( n = 23) ( P = 0·01). The autologous and allogeneic HSCT groups differed in terms of 5‐year event‐free survival ( EFS ) (38% vs. 50%, P = 0·63), cumulative incidence of progress or relapse (49% vs. 28%, P = 0·25), and treatment‐related mortality (12% vs. 25%, P = 0·40). However, these differences were not significant. Patients with non‐ CR at autologous HSCT had a significantly lower EFS rate (14% vs. 48%, P = 0·03). Conversely, although those with non‐ CR at allogeneic HSCT had a lower EFS rate, this was not significant (44% vs. 63%, P = 0·26). Reduced‐intensity conditioning regimens were used for three of the 16 allogeneic HSCT s received by patients with non‐ CR . These three patients achieved CR , surviving 32–65 months after HSCT . These results demonstrated that allogeneic HSCT might be a treatment option for patients who do not achieve CR through conventional chemotherapy.